TW202535952A - 治療多發性骨髓瘤的方法 - Google Patents
治療多發性骨髓瘤的方法Info
- Publication number
- TW202535952A TW202535952A TW114114347A TW114114347A TW202535952A TW 202535952 A TW202535952 A TW 202535952A TW 114114347 A TW114114347 A TW 114114347A TW 114114347 A TW114114347 A TW 114114347A TW 202535952 A TW202535952 A TW 202535952A
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- patients
- group
- dexamethasone
- pomalidomide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797876P | 2019-01-28 | 2019-01-28 | |
| US62/797,876 | 2019-01-28 | ||
| US201962847826P | 2019-05-14 | 2019-05-14 | |
| US62/847,826 | 2019-05-14 | ||
| US201962861954P | 2019-06-14 | 2019-06-14 | |
| US62/861,954 | 2019-06-14 | ||
| US201962899094P | 2019-09-11 | 2019-09-11 | |
| US62/899,094 | 2019-09-11 | ||
| US201962931014P | 2019-11-05 | 2019-11-05 | |
| US62/931,014 | 2019-11-05 | ||
| EP19306554.7 | 2019-12-03 | ||
| EP19306554 | 2019-12-03 | ||
| US201962943716P | 2019-12-04 | 2019-12-04 | |
| US62/943,716 | 2019-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202535952A true TW202535952A (zh) | 2025-09-16 |
Family
ID=69646031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW114114347A TW202535952A (zh) | 2019-01-28 | 2020-01-30 | 治療多發性骨髓瘤的方法 |
| TW109102902A TWI904081B (zh) | 2019-01-28 | 2020-01-30 | 治療多發性骨髓瘤的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109102902A TWI904081B (zh) | 2019-01-28 | 2020-01-30 | 治療多發性骨髓瘤的方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11939390B2 (https=) |
| EP (2) | EP3917961A1 (https=) |
| JP (2) | JP7712206B2 (https=) |
| KR (1) | KR20210120048A (https=) |
| CN (2) | CN120754030A (https=) |
| AU (1) | AU2020215692A1 (https=) |
| BR (1) | BR112021014699A2 (https=) |
| CA (1) | CA3127928A1 (https=) |
| CO (1) | CO2021011034A2 (https=) |
| IL (2) | IL321343A (https=) |
| MA (1) | MA54860A (https=) |
| MX (1) | MX2021009079A (https=) |
| SG (1) | SG11202108029XA (https=) |
| TW (2) | TW202535952A (https=) |
| WO (1) | WO2020160020A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| JP6730260B2 (ja) | 2014-09-12 | 2020-07-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
| JP7712206B2 (ja) | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
| EP3969004A1 (en) * | 2019-05-14 | 2022-03-23 | Sanofi | Methods of administering anti-cd38 antibody to treat multiple myeloma |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| IL293563A (en) * | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| EP4192511A1 (en) * | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugates targeting cd46 and methods of use thereof |
| IL302640A (en) * | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| US20240058464A1 (en) * | 2021-01-07 | 2024-02-22 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
| CN114219787B (zh) * | 2021-12-17 | 2024-08-06 | 三峡大学 | 一种初诊多发性骨髓瘤预后分期系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| LT2882441T (lt) * | 2012-08-09 | 2020-07-27 | Celgene Corporation | Su imunitetu susijusių ir uždegiminių ligų gydymas |
| WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| HUE054271T2 (hu) * | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| IL256242B2 (en) * | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US20180153989A1 (en) * | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| JP7712206B2 (ja) | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
-
2020
- 2020-01-28 JP JP2021543372A patent/JP7712206B2/ja active Active
- 2020-01-28 WO PCT/US2020/015455 patent/WO2020160020A1/en not_active Ceased
- 2020-01-28 IL IL321343A patent/IL321343A/en unknown
- 2020-01-28 CN CN202510783436.0A patent/CN120754030A/zh active Pending
- 2020-01-28 AU AU2020215692A patent/AU2020215692A1/en active Pending
- 2020-01-28 US US16/775,025 patent/US11939390B2/en active Active
- 2020-01-28 EP EP20706606.9A patent/EP3917961A1/en active Pending
- 2020-01-28 SG SG11202108029XA patent/SG11202108029XA/en unknown
- 2020-01-28 CA CA3127928A patent/CA3127928A1/en active Pending
- 2020-01-28 EP EP25172506.5A patent/EP4588484A3/en active Pending
- 2020-01-28 MX MX2021009079A patent/MX2021009079A/es unknown
- 2020-01-28 KR KR1020217027098A patent/KR20210120048A/ko active Pending
- 2020-01-28 BR BR112021014699A patent/BR112021014699A2/pt unknown
- 2020-01-28 MA MA054860A patent/MA54860A/fr unknown
- 2020-01-28 CN CN202080024773.7A patent/CN114026121A/zh active Pending
- 2020-01-28 IL IL285110A patent/IL285110B2/en unknown
- 2020-01-30 TW TW114114347A patent/TW202535952A/zh unknown
- 2020-01-30 TW TW109102902A patent/TWI904081B/zh active
-
2021
- 2021-08-23 CO CONC2021/0011034A patent/CO2021011034A2/es unknown
-
2024
- 2024-02-16 US US18/443,878 patent/US20240190984A1/en active Pending
-
2025
- 2025-07-09 JP JP2025115594A patent/JP2025148430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148430A (ja) | 2025-10-07 |
| BR112021014699A2 (pt) | 2021-11-23 |
| EP3917961A1 (en) | 2021-12-08 |
| CN120754030A (zh) | 2025-10-10 |
| TW202043283A (zh) | 2020-12-01 |
| CN114026121A (zh) | 2022-02-08 |
| US20200239589A1 (en) | 2020-07-30 |
| CA3127928A1 (en) | 2020-08-06 |
| IL285110B2 (en) | 2025-11-01 |
| AU2020215692A1 (en) | 2021-09-16 |
| MA54860A (fr) | 2022-05-04 |
| US20240190984A1 (en) | 2024-06-13 |
| SG11202108029XA (en) | 2021-08-30 |
| EP4588484A2 (en) | 2025-07-23 |
| WO2020160020A1 (en) | 2020-08-06 |
| IL285110B1 (en) | 2025-07-01 |
| IL285110A (en) | 2021-09-30 |
| MX2021009079A (es) | 2022-02-10 |
| TWI904081B (zh) | 2025-11-11 |
| JP7712206B2 (ja) | 2025-07-23 |
| US11939390B2 (en) | 2024-03-26 |
| EP4588484A3 (en) | 2025-10-15 |
| JP2022518060A (ja) | 2022-03-11 |
| CO2021011034A2 (es) | 2021-09-09 |
| KR20210120048A (ko) | 2021-10-06 |
| IL321343A (en) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI904081B (zh) | 治療多發性骨髓瘤的方法 | |
| Lonberg | Fully human antibodies from transgenic mouse and phage display platforms | |
| CN118924895A (zh) | 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案 | |
| TW202140016A (zh) | 用於治療癌症之ｅｇｆｒ抑制劑及ｒｏｒ１抑制劑之組合 | |
| JP2025138745A (ja) | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 | |
| TW202541838A (zh) | 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途 | |
| US20250177519A1 (en) | Use of isatuximab in combination with other agents for the treatment of multiple myeloma | |
| RU2838203C2 (ru) | Способы лечения множественной миеломы | |
| TWI922320B (zh) | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 | |
| CA3048198A1 (en) | Methods of treating multiple myeloma | |
| TW202304981A (zh) | 抗ｉｌ－２７抗體及其用途 | |
| RU2858309C2 (ru) | Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы | |
| TW202233235A (zh) | 艾薩妥昔單抗用於治療多發性骨髓瘤的用途 | |
| TW202610683A (zh) | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 | |
| US20250134997A1 (en) | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy in ctdna high risk patients | |
| WO2026033458A1 (en) | DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER |